Blackstone Signals Confidence in Teva’s Pivot to Innovation with $400 Million Investment

Blackstone (NYSE: BX) has entered into a $400 million financing agreement with Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) to fund the clinical development of duvakitug, a monoclonal antibody targeting autoimmune diseases. The investment focuses on the drug's potential to treat ulcerative colitis and Crohn's disease. Currently in Phase 3 trials in partnership with Sanofi (NASDAQ: SNY), duvakitug has already demonstrated durable efficacy in Phase 2 studies over a 44-week period. Blackstone Life Sciences, which boasts an 86% success rate for Phase 3 drug investments, views the therapy as a potential best-in-class treatment in a growing market. Beyond duvakitug, Teva is advancing several other late-stage assets to diversify its revenue streams. These include an olanzapine long-acting injectable for schizophrenia and TEV-'248, a dual-action asthma rescue inhaler currently in Phase 3. The company is also awaiting FDA approval for five biosimilars, including versions of Eylea, Prolia, Simponi, and Xgeva. This strategic pivot is being recognized by credit agencies and analysts alike. S&P Global upgraded Teva’s rating to BB+ in December 2025, while Moody’s shifted its outlook to positive. Market sentiment remains strongly positive, with 12 of 13 surveyed analysts maintaining a 'buy' or 'strong buy' rating on the stock. Blackstone's involvement provides both capital and a professional endorsement of Teva's R&D capabilities. In exchange for the funding, Blackstone is set to receive milestone payments and low single-digit royalties on global sales of duvakitug upon regulatory approval.